10.3.2021 17:15:00 CET | Monsenso |
Selskabsmeddelelse
Monsenso fremlægger tilfredstillende årsregnskab med omsætning i 2020 som forventet og vækstforventninger for 2021 omkring 70%.
Selskabsmeddelelse nr. 4-2021
København den 10. marts 2021
Monsensos årsrapport for 2020 blev godkendt af bestyrelsen i dag.
Hovedpunkter
Omsætning steg 3% til TDKK 9.063 (2019: TDKK 8.780).
Den kommercielle omsætning steg med 78% og nåede TDKK 6.745 (2019: TDKK 3.790).
Primært driftsresultat (EBITDA) var på TDKK -2.298 (2019: TDKK 3.410).
Pengestrømme fra driftsaktivitet var på TDKK 2.906 (2019: TDKK -37).
Succesfuld introduktion på Nasdaq First North Growth Market Denmark med bruttoprovenu på TDKK 20.000 og 238% overtegning.
Egenkapital pr. 31. december 2020 var på TDKK 18.654, (2019 TDKK 4.093).
Likvide beholdninger pr. 31. december 2020 var på TDKK 12.463 (2019 TDKK 220).
International ekspansion
Monsenso indgik betydelige nye kontrakter indenfor farmaceutisk industri for dels at støtte real-world evidence projekter og dels som tillæg til medicinering.
Monsenso-løsningen er ude i 12 lande mod 9 lande i 2019.
Monsenso åbnede kontor i Storbritannien for at udvide tilstedeværelsen på dette marked med direkte lokal repræsentation.
Covid-19 forsinkede nogle af vores implementerings-projekter, men affødte også forbedrede muligheder indenfor digital sundhed, telemedicin og fjern-monitorering.
CEO Thomas Lethenborg udtaler:
2020 var et meget spændende år for Monsenso. På trods af de specielle forhold forårsaget af Covid-19 opnåede Monsenso en vellykket børsintroduktion (IPO) på Nasdaq First North Growth Market Denmark og fortsatte sin vækstrejse med nye internationale kunde- og partner engagementer, samt udvidede teamet i overensstemmelse med vækstplanen.
Provenuet fra børsintroduktionen bruges til at støtte den organisatoriske udvidelse, der er nødvendig for indfri den internationale vækstplan hen imod en forretning på DKK 75m i år 2024.
Forventninger til 2021
Monsenso forventer at fortsætte vækstrejsen og forventer en vækst i omsætningen i 2021 på omkring omkring 70%. Omsætningen forventes mellem DKK 14m og DKK 16m og EBITDA forventes mellem DKK -4,8m og DKK -5,6m.
Grundet Covid-19 og det faktum at omsætningen afhænger af fremdrift i en række store projekter er dette forbundet med usikkerhed.
Hovedtal
(‘000 DKK)
2020
2019
Omsætning
9.063
8.780
Primært driftsresultat (EBITDA)
(2.298)
3.410
Årets resultat
(4.713)
(225)
Pengestrømme fra driftsaktivitet
2.906
(37)
Likvide beholdninger ultimo
28.604
11.762
Egenkapital ultimo
18.654
4.093
Resultat pr. aktie (DKK)
(0,41)
(0,02)
Antal fuldtidsansatte ultimo (FTE)
19
9
Thomas Lethenborg præsenterer Årsrapport 2020 på et webinar torsdag 11. marts 2021, kl. 13.00.
Link til webcast er https://hcandersencapital.dk/event/monsenso-praesentation-af-aarsrapporten/
Ansvarsfraskrivelse
Denne rapport indeholder fremadrettede udsagn, der er baseret på ledelsens nuværende forventninger. Alle udsagn om fremtiden er underlagt iboende risici og usikkerheder, og mange faktorer kan føre til faktiske resultater og udvikling, der afviger væsentligt fra det, der er udtrykt eller underforstået i sådanne udsagn.
Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til:
Selskabet:
Bestyrelsesformand Jukka P. PertolaTlf. +45 20 19 82 20E-mail: jukka.pertola@pertola.com
CEO Thomas LethenborgTlf. +45 21 29 88 27E-mail: lethenborg@monsenso.com
Certified Adviser:
Norden CEF ApSJohn NordenTlf. +45 20 72 02 00E-mail: jn@nordencef.dk
Om Monsenso
Monsenso er en innovativ virksomhed, som tilbyder en digital sundhedsløsning. Vores mission er at bidrage til bedre mental sundhed til flere personer og lavere omkostninger. Vores løsning bidrager til optimering af behandlingen for psykiske lidelser og giver et detaljeret overblik over patienters mentale sundhed via indsamling af data om mental tilstand, adhærens og adfærd. Løsningen forbinder patienter, omsorgspersoner og behandlere for at muliggøre en personligt tilpasset behandling, distancebehandling samt tidlig opsporing og intervention. Baseret på vedvarende forskning og udvikling er vores team opsat på at udvikle løsninger, der passer ind i brugernes liv, øger patienters livskvalitet og forbedrer effekten af behandlingen. Få mere at vide på www.monsenso.com
Vedhæftninger
Download selskabsmeddelelse.pdf
Annual report 2020.Monsenso.pdf
10.3.2021 17:15:00 CET | Monsenso |
Company Announcement
Monsenso presents satisfactory annual report with revenue for 2020 as expected and anticipated growth rate of close to 70% for 2021.
Company announcement no. 4-2021
Copenhagen, 2021.03.10.
Monsenso’s annual report for 2020 was approved by the Board of Directors today.
Performance highlights
The total revenue increased by 3% to DKK 9,063k (2019: DKK 8,780k).
Commercial revenue increased by 78% reaching DKK 6,745k (2019: DKK 3,790k).
EBITDA was DKK -2,298k (2019: DKK 3,410k).
Cash flows from operating activities was DKK 2,906k (2019: DKK -37k).
Capital increase of DKK 20,000k from successful IPO at Nasdaq First North Growth Market with 238% oversubscription.
The total equity as of December 31, 2020 amounted to DKK 18,654k (2019 DKK 4,093k).
Total cash and cash equivalents as of December 31, 2020 amounted to DKK 12,463k (2019 DKK 220k).
The organisation doubled; reaching 19 employees (converted to full-time employees) at the end of year 2020.
International expansion
Monsenso signed significant new contracts in the pharmaceutical sector to support both real-world evidence projects and digital companion projects for new medications.
The Monsenso solution has been implemented across 12 countries, against 9 countries in 2019.
We opened an office in the UK to expand presence in the market with direct and local representation.
Covid-19 impacted the pace of some of our implementation projects, but also gave digital health, remote care and remote monitoring solutions an awareness boost that the company benefits from.
CEO Thomas Lethenborg states:
2020 was a very exciting year for Monsenso. Despite the special conditions caused by Covid-19, Monsenso achieved a successful initial public offering (IPO) at Nasdaq First North Growth Market and continued its growth journey with new international customer and partner engagements as well as expansion of the team in accordance with the growth plan.
The proceeds from the IPO will be used to support the organisational expansion needed to achieve the international growth plan towards achieving a DKK 75m business by 2024.
Outlook for 2021
Monsenso expects to continue the growth journey and anticipates a growth in revenue for 2021 of approximately 70%. Guidance on revenue is DKK 14m to DKK 16m and on EBITDA DKK -4.8m to DKK -5.6m.
Due to Covid-19 and the fact that revenue is depending on progress in a number of large projects, the expectations are associated with uncertainty.
Key figures
(‘000 DKK)
2020
2019
Revenue
9.063
8.780
EBITDA
(2.298)
3.410
Profit (loss) for the year
(4,713)
(225)
Cash flows from operating activities
2.906
(37)
Total assets, end of year
28.604
11.762
Equity, end of year
18.654
4.093
Net profit per share (DKK)
(0,41)
(0,02)
End-of-year, number of employees (FTE)
19
9
Thomas Lethenborg will present the Annual report on a webinar Thursday March 11, 2021, at 13.00 CET.
Link to webcast is https://hcandersencapital.dk/event/monsenso-praesentation-af-aarsrapporten/
Disclaimer
This report contains forward-looking statements which are based on the current expectations of the management. All statements regarding the future are subject to inherent risks and uncertainties, and many factors can lead to actual results and developments deviating substantially from what has been expressed or implied in such statements.
Any inquiries regarding this notice should be directed to:
Monsenso:
Chairman of the board Jukka P. Pertola Tel. +45 20 19 82 20 E-mail: jukka.pertola@pertola.com
CEO Thomas Lethenborg Tel. +45 21 29 88 27 E-mail: lethenborg@monsenso.com
Certified Adviser:
Norden CEF ApS John Norden Tel. +45 20 72 02 00 E-mail: jn@nordencef.dk
About Monsenso
Monsenso is an innovative technology company offering a digital health solution. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit www.monsenso.com
Attachments
Download announcement as PDF.pdf
Annual report 2020.Monsenso.pdf
